Healthcare company Revival partnership to establish robotics firm focusing on gastrointestinal procedures, partnered with Olympus
Olympus, a Tokyo-based medtech company, and Revival Healthcare Capital, a medtech-focused investment firm, have joined forces to co-found a new company named Swan EndoSurgical. The goal of this partnership is to develop an innovative endoluminal robotics platform for gastrointestinal (GI) treatments, with the potential to invest up to $458 million in the venture[1][2][3].
Swan EndoSurgical aims to revolutionize GI treatments by creating a minimally invasive, endoluminal robotic system. This system, designed to navigate the GI tract similarly to an endoscope, will feature flexible robotic arms capable of treating tumors, lesions, and other diseases. The technology is expected to expand procedural capabilities for physicians, offer organ-sparing care, and enhance patient outcomes through less invasive therapeutic interventions[4].
Olympus will contribute its core visualization and endoscopy technologies, while Revival will take a majority equity stake in Swan EndoSurgical, with an option for Olympus to acquire the startup at a later date[4]. This strategic partnership models a "build-to-buy" approach, where Olympus has an option to acquire Swan at a predetermined value based on investment milestones, ensuring alignment on advancing GI robotics innovation with significant investment and technology expertise from both parties[1][2][4].
The collaboration between Olympus and Revival is expected to help reshape the GI market by expanding physicians' procedural capabilities. The formation of Swan EndoSurgical is also anticipated to bring good jobs to the U.S., according to AdvaMed CEO Scott Whitaker. This unique partnership between two AdvaMed members is expected to bolster medtech's already strong manufacturing and research and development presence in the U.S[5].
It's worth noting that this partnership comes after Olympus has faced previous issues related to its devices, including import blocks, FDA warnings, and a troubling disregard for patient safety[6]. The new venture, however, presents an opportunity for Olympus to reaffirm its commitment to patient safety and innovation in the medtech industry.
The new robotic system, if successful, is intended to offer patients safer and more effective treatment with faster recovery times[3]. As the medtech ecosystem continues to grow, with investments like this one, it's clear that advancements in technology and healthcare are on the horizon.
- BusinessWire
- FierceBiotech
- Endpoints News
- MedCity News
- MassDevice
- Stat News
- The collaboration between Olympus and Revival Healthcare Capital, as reported by BusinessWire, aims to invest up to $458 million in the development of an innovative endoluminal robotics platform for gastrointestinal (GI) treatments.
- Swan EndoSurgical, the new company co-founded by Olympus and Revival Healthcare Capital, is expected to revolutionize GI treatments with its minimally invasive, endoluminal robotic system, as mentioned in MedCity News.
- This robotic system, designed to navigate the GI tract, will feature flexible robotic arms capable of treating tumors, lesions, and other diseases, according to Endpoints News.
- Olympus will contribute its core visualization and endoscopy technologies, as stated in MedCity News, while Revival will take a majority equity stake in Swan EndoSurgical with an option for Olympus to acquire the startup.
- This strategic partnership between Olympus and Revival models a "build-to-buy" approach, as explained in both FierceBiotech and MassDevice, allowing Olympus an option to acquire Swan at a predetermined value based on investment milestones.
- The formation of Swan EndoSurgical is anticipated to bring good jobs to the U.S., as reported by MassDevice, and bolster medtech's already strong manufacturing and research and development presence, according to AdvaMed CEO Scott Whitaker.
- The new venture presents an opportunity for Olympus to reaffirm its commitment to patient safety and innovation in the medtech industry, as highlighted by Stat News, following previous issues related to its devices.
- If successful, the new robotic system is intended to offer patients safer and more effective treatment with faster recovery times, as reported by Endpoints News, enhancing healthcare and wellness through advancements in medtech science and technology.
- The investment in Swan EndoSurgical by Olympus and Revival Healthcare Capital, as well as other investments in the medtech ecosystem, indicate that significant investing in healthcare and technology is ongoing for business growth and prosperity.
- As medtech companies continue to focus on innovation, research, and AI technology, the potential for groundbreaking discoveries and improvements in health-and-wellness, fitness-and-exercise, and medical-conditions treatments is endless.
